Logo for Rain Therapeutics Inc

Rain Therapeutics Inc Investor Relations Material

Latest events

Logo for Rain Therapeutics Inc

Q2 2023

Rain Therapeutics Inc
Logo for Rain Therapeutics Inc

Q3 2023

9 Nov, 2023
Logo for Rain Therapeutics Inc

Q2 2023

10 Aug, 2023
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies
Rain Therapeutics Inc, a clinical-stage precision oncology company, engages in developing therapies that target oncogenic drivers in the United States. Its lead product candidate is milademetan, a small molecule oral inhibitor of mouse double minute 2, which is oncogenic in various cancers. The company is also developing milademetan which is in Phase 3 clinical trial for liposarcoma, Phase II clinical trial for solid tumors, and Phase II clinical trial for intimal sarcoma, as well as RAD52 which is in preclinical trials for tumors, including breast, ovarian, pancreatic, prostate, and other cancers.